# Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease

> **NCT03543540** · PHASE1 · COMPLETED · sponsor: **ImmusanT, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Celiac Disease
- Intestinal Disease
- Malabsorption Syndromes
- Gastrointestinal Disease
- Digestive System Diseases
- Metabolic Disease
- Coeliac Disease
- Gluten Sensitivity

## Interventions

- **BIOLOGICAL:** Nexvax2
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03543540
- **Lead sponsor:** ImmusanT, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2018-09-10
- **Final completion:** 2018-09-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2018-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03543540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03543540, "Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03543540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*